Monoclonal antibodies

The U.S. Food and Drug Administration has given Roche’s multiple sclerosis drug ocrelizumab, brand name Ocrevus approval for the treatment of both relapsing and primary progressive forms of the disease. Ocrelizumab is a humanized anti-CD20 monoclonal antibody which targets CD20 marker on B lymphocytes. It is a slightly modified version of Biogen/Genentech’s existing therapy Rituxan/Rituximab… Read more

Lanadelumab, a new drug to prevent attacks of hereditary angioedema, has shown promising results in a phase 1b clinical trial, a new paper reports. Hereditary angioedema (HAE) is a rare blood disorder characterized by recurrent swelling of tissues in the face, hands, gastrointestinal tract and airway. HAE is caused by mutations that reduce the production… Read more

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody, a protein that attacks viruses, isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection. The… Read more

They are tiny magic bullets that are quietly shaping the lives of millions of patients around the world. Produced in the lab, invisible to the naked eye, relatively few people are aware of these molecules’ existence or where they came from. Yet monoclonal antibodies are contained in six out of ten of the world’s bestselling… Read more